In summary, our study demonstrated the antitumor efficacy of the combination of DNMT inhibitors and PARP inhibitors in patient-derived CCA cell lines and patient-derived CCA xenograft models. The gene discussed is DNMT1; the disease is cholangiocarcinoma.